Can Veracyte’s Decipher Prostate test change who gets chemotherapy in metastatic prostate cancer?
Can Veracyte’s Decipher Prostate test change chemotherapy decisions in metastatic prostate cancer? Find out what ENZAMET data means today.
NUBEQA data at AUA 2026 sharpens Bayer’s mCSPC positioning against androgen receptor rivals
Bayer has stronger NUBEQA mCSPC data. The tougher test is whether clinicians view ARASEC as confirmatory or merely supportive.
Why AstraZeneca’s TRUQAP ODAC vote could reshape PTEN-deficient prostate cancer treatment
TRUQAP has ODAC support, but toxicity and survival maturity still matter. AstraZeneca’s prostate cancer expansion now faces FDA’s final test.
Foresee Pharmaceuticals wins CHMP backing for CAMCEVI 21 mg, expanding prostate cancer treatment options in Europe
CHMP backs CAMCEVI 21 mg for advanced prostate cancer in the EU. Discover what the decision means for androgen deprivation therapy and oncology markets.
Can Alessa’s Enolen implant change how early-stage prostate cancer is treated?
Alessa’s Enolen earns FDA fast track for localized prostate cancer. Find out how this implant could redefine early-stage treatment and challenge current norms.